MMC Ventures

MMC Ventures is a London-based research-led venture firm that has built its reputation on understanding applied AI before it was fashionable. The firm publishes a long-running State of AI report and runs an internal research function that informs every investment decision. For physician-AI founders, that orientation matters; MMC partners can hold a substantive technical conversation about model architectures, data pipelines, and clinical deployment risk without needing a translator in the room.

The thesis centres on data-driven enterprise software, with healthcare as one of several verticals where applied AI is changing how work gets done. Within healthcare the team has shown a clear preference for AI/ML platforms, clinical workflow software, diagnostics, and infrastructure that helps providers and life sciences companies use data better. They are less interested in pure consumer wellness or non-AI digital health point solutions. The bar on technical defensibility, data strategy, and ICP clarity is high.

Check sizes typically land between one and five million dollars at seed and Series A, with the firm willing to lead and take a board seat. They follow on through subsequent rounds and have a structured process for preparing portfolio companies for Series B and beyond. The geographic focus is the UK and Europe, with London as the home base; US-based founders should look elsewhere unless the market wedge is clearly European.

MMC’s team is a mix of investing partners and a dedicated research and data science group, which is unusual for a firm of this size. The research function does primary work on AI, data infrastructure, and vertical SaaS, and that work is shared with founders during diligence and after the cheque clears. Portfolio support extends into hiring, go-to-market, and follow-on fundraising.

The right way to reach the firm is a warm introduction from an existing MMC portfolio CEO, an operator in the London AI scene, or one of the firm’s research collaborators. The MMC website and research reports get read closely, and founders who can show genuine engagement with the firm’s published thinking tend to land warmer first meetings. Approach when you have a working product, early commercial validation, and a credible AI moat that survives more than a single demo. Bring a clear data strategy, a sober view on regulatory and clinical evidence requirements, and a defined view on who buys, who uses, and who pays. The right moment to engage is one to two quarters before a round, with enough time for the team to dig into your data and references. Founders chasing AI hype without a clinical wedge, and founders without UK or European market focus, should expect a polite pass; founders building serious applied AI for healthcare will find a partner who can engage at depth.